Drugs / JNJ-42165279
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT03564379 | Jun → Aug 2018 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02169973 | Feb → Jul 2014 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02065739 | Jan → Mar 2014 | — | Janssen Pharmaceutica N.V., Belgium | Completed | No outcome recorded |
| Phase 1 | NCT01964651 | Oct 2013 → Oct 2014 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01826786 | Aug 2013 → Aug 2014 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01650597 | Aug 2011 → May 2012 | — | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 23 trials · 3 missed | ||||||
| Phase 2 | NCT03664232 | Nov 2018 → Oct 2022 | autism spectrum disorder | Janssen Research & Development, LLC | Completed | Missed primary |
| Phase 2 | NCT02498392 | Oct 2015 → Feb 2019 | anxiety, depressive disorder | Janssen Research & Development, LLC | Completed | Missed primary |
| Phase 2 | NCT02432703 | Jun 2015 → Aug 2018 | phobic disorder | Janssen Research & Development, LLC | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-42165279 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01826786 ↗ |
| Action | Inhibit | “The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279” PMID 33070154 ↗ Oct 2020 |
| Modality | Small molecule | — CHEMBL4297294 ↗ |
| Route | Oral | “route=oral use. One single dose administered orally.” NCT01650597 ↗ |
| Target | FAAH | “JNJ-42165279 is a selective inhibitor of fatty acid amide hydrolase (FAAH)” PMID 33070154 ↗ Oct 2020 |